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ABSTRACT
Background. Large multicenter series on outcomes and
predictors of survival after distal pancreatectomy (DP) for
pancreatic ductal adenocarcinoma (PDAC) are scarce.
Methods. Adults who underwent DP for PDAC in 17
Dutch pancreatic centers between January 2005 and
September 2013 were analyzed retrospectively. The pri-
mary outcome was survival, and predictors of survival
were identified using Cox regression analysis.
Results. In total, 761 consecutive patients after DP were
assessed, of whom 620 patients were excluded because of
non-PDAC histopathology (n = 616) or a lack of data
(n = 4), leaving a total of 141 patients included in the
study [45 % (n = 63) male, mean age 64 years
(SD = 10)]. Multivisceral resection was performed in 43
patients (30 %) and laparoscopic resection was performed
in 7 patients (5 %). A major complication (Clavien–Dindo
score of III or higher) occurred in 46 patients (33 %). Mean
tumor size was 44 mm (SD 23), and histopathological
examination showed 70 R0 resections (50 %), while 30-
day and 90-day mortality was 3 and 6 %, respectively.
Overall, 63 patients (45 %) received adjuvant chemother-
apy. Median survival was 17 months [interquartile range
(IQR) 13–21], with a median follow-up of 17 months (IQR
8–29). Cumulative survival at 1, 3 and 5 years was 64, 29,
and 22 %, respectively. Independent predictors of worse
postoperative survival were R1/R2 resection [hazard ratio
(HR) 1.6, 95 % confidence interval (CI) 1.1–2.4], pT3/pT4
stage (HR 1.9, 95 % CI 1.3–2.9), a major complication
(HR 1.7, 95 % CI 1.1–2.5), and not receiving adjuvant
chemotherapy (HR 1.5, 95 % CI 1.0–2.3).
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Conclusion. Survival after DP for PDAC is poor and is
related to resection margin, tumor stage, surgical compli-
cations, and adjuvant chemotherapy. Further studies should
assess to what extent prevention of surgical complications
and more extensive use of adjuvant chemotherapy can
improve survival.
Pancreatic ductal adenocarcinoma (PDAC) is the fifth
leading cause of cancer death and is associated with a
dismal 5-year cumulative survival of 6 %.1 PDAC is one of
the most aggressive cancers and, to date, only surgery, in
combination with adjuvant chemotherapy, has the potential
to achieve long-term survival. Unfortunately, only a
minority (15–20 %) of patients are eligible for surgical
resection at the time of diagnosis, mainly because of the
late onset of nonspecific symptoms, resulting in the fre-
quent presence of metastatic or locally advanced
disease.2–4 Of the two main surgical procedures for PDAC,
distal pancreatectomy (DP) has traditionally been consid-
ered less complicated (i.e. less complications, lower
mortality) than pancreatoduodenectomy. Merely one-fifth
of all pancreatic cancers is located in the pancreatic tail
and, of these patients, 80 % have unresectable disease due
to metastasis or major vessel tumor invasion.4–7
Of the patients who can undergo DP for PDAC, reports
on survival in large cohorts are scarce, as opposed to
pancreatoduodenectomy.8,9 This may be explained by the
low volume characteristics of DP for PDAC. To date, two
multicenter series on survival after DP for PDAC have
been published. The first series from the US found a
median postoperative survival of 16 months, whereas a
French study reported a median postoperative survival of
35 months.10,11 These series also assessed independent
predictors of survival, but again with conflicting outcomes.
Therefore, it is not yet clear how outcomes in these patients
can potentially be improved. This multicenter study was
designed to assess overall survival and predictors of sur-
vival after DP for PDAC.
METHODS
Patients and Design
This was a nationwide retrospective study including all
consecutive adult patients who had undergone DP for
PDAC in 1 of 17 pancreatic centers of the Dutch Pancreatic
Cancer Group (DPCG) between 1 January 2005 and 1
September 2013. Each of these centers performs at least 20
pancreatoduodenectomies annually, as of 2007. Patients
were excluded when postoperative histopathological diag-
nosis was not PDAC or when essential data on the surgical
procedure or pathology report were lacking. This study was
conducted according to the Strengthening the Reporting of
Observational studies in Epidemiology (STROBE) state-
ment.12 Data were registered anonymously and evaluated
retrospectively, without burden for the patient. Therefore,
according to the local Medical Ethics Review Committee,
informed consent was not required. Socioeconomic status
was not considered to have any influence on access of care
in this series as in The Netherlands every citizen is covered
by a health insurance policy.
Surgical Technique and Oncologic Treatment Regimen
Preoperative chemotherapy or radiotherapy was not
used within the current timeframe. DP was performed via
an open or laparoscopic approach. In case of proven or
suspected malignant disease, a subsequent splenectomy
was generally performed. Routine lymphadenectomy was
performed according to the International Study Group on
Pancreatic Surgery (ISGPS) recommendations, and also
before the ISGPS publication regarding standard lym-
phadenectomy.13 The pancreas was transected using either
sharp transection or a stapling device. Additional sutures or
an absorbable fibrin sealant patch were used in a small
subset of patients at the discretion of the surgeon. In all
patients, a surgical drain was placed near the pancreatic
remnant and left subphrenic space. Patients received
adjuvant chemotherapy when they were fit enough (ac-
cording to the medical oncologist), and they chose to
receive it. As of 2011, the Dutch guideline on pancreatic
cancer advised the use of adjuvant gemcitabine after
resection for PDAC.14
Definitions
Multivisceral resection was defined as resection of any
organ or a part of an organ besides the pancreas, spleen,
and adrenal gland. Resection margins, including transec-
tion and circumferential margins, were classified as R0
(distance margin to tumor C1 mm), R1 (distance margin to
tumor\1 mm), or R2 (macroscopically positive margin).15
PDAC stages were classified according to the American
Joint Committee on Cancer (AJCC; 7th edition) staging by
pT, pN, and pM stages, and overall cancer stages 1A, 1B,
2A, 2B, III, and IV.16 Postoperative complications were
scored using the Clavien–Dindo classification of surgical
complications,17 and major complications were defined as
complications with a Clavien–Dindo score of III or higher.
Additionally, specific complications such as grade B/C
postoperative pancreatic fistula, delayed gastric emptying,
and postpancreatectomy hemorrhage were all scored using
the recommended ISGPS definitions.18–20 Surgical site
infection was defined using the Centers for Disease Control
and Prevention (CDC) definition.21
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Outcomes and Data Collection
Data were collected from patient records and patient
charts with daily notes. Baseline parameters collected
included sex, age, body mass index, American Society of
Anesthesiologists (ASA) physical status, history of
abdominal surgery, and preoperative signs of ingrowth in
adjacent organs. The primary study outcome was survival.
Secondary outcomes were intraoperative and postoperative
parameters, such as splenectomy, multivisceral resection,
procedure time, intraoperative blood loss, resection mar-
gins, lymph node retrieval, postoperative pancreatic fistula,
delayed gastric emptying, postpancreatectomy hemorrhage,
surgical site infection, intensive care unit admission, length
of stay, readmission within 30 days, adjuvant chemother-
apy, 30-day mortality, 90-day mortality, and 1-, 3-, and 5-
year cumulative survival. Complications were collected up
to 90 days postoperatively. Clavien–Dindo morbidity
scores were registered when they were recorded by the
hospital where the patient was operated, while mortality
rates were used to display all deaths within a mentioned
timeframe. Survival data were collected in February 2015
for all patients using the municipal personal records data-
base, a registry that contains the personal details of every
Dutch inhabitant.
Statistical Analysis
Data were analyzed using IBM SPSS version 20.0
(IBM Corporation, Armonk, NY, USA). Dichotomous data
were expressed as proportions, and continuous data were
expressed as means and standard deviations (SDs) or
medians and interquartile ranges (IQRs), depending on
their distribution. Dichotomous data were compared using
a v2 analysis, while continuous data were compared using
an independent Student’s t test or Mann–Whitney U test as
appropriate. Survival was assessed using Kaplan–Meier
analysis, from the date of DP until death or last moment of
follow-up (censored observation). Comparison of sub-
groups (i.e. patients who received chemotherapy vs.
patients who did not receive chemotherapy, and patients
who underwent DP only vs. patients who underwent mul-
tivisceral resection) with regard to survival was performed
using a log-rank test. Univariable and multivariable Cox
regression analyses with backward selection were per-
formed to identify predictors of survival. Parameters with a
p value\ 0.1 in the univariable analysis were included in
the multivariable analysis. Results of the univariable and
multivariable analyses were expressed as hazard ratios
(HRs) with corresponding 95 % confidence intervals (CIs).
A subgroup analysis comparing patients who received
adjuvant chemotherapy with patients who did not receive
adjuvant chemotherapy was performed. A two-tailed p
value\ 0.05 was considered statistically significant.
RESULTS
Patient Characteristics
In total, 761 patients had undergone DP within the study
period, as described previously.22 For this study, 620
patients were excluded: 616 patients because the
histopathological diagnosis was other than PDAC, and 4
patients because data were lacking. Therefore, 141 patients
who had undergone DP for PDAC were included in this
study (Table 1). The median annual volume increased from
seven procedures in the first 3 years of the study period to
25 procedures in the last 3 years.
Intraoperative and Pathology Outcomes
DP with splenectomy was performed in 124 patients
(88 %) and multivisceral resection was performed in 43
patients (30 %), as shown in Table 2. Laparoscopic
resection was performed in seven patients (5 %). Median
procedure time was 194 min (IQR 150–270), and median
intraoperative blood loss was 800 mL (IQR 495–1618). An
absorbable fibrin sealant patch was used in 17 patients
(12 %). Pathology reports demonstrated a mean tumor size
of 44 mm (SD 23). Microscopically radical transection and
circumferential resection margins (R0 resection) were
obtained in 70 patients (50 %), of whom 17 patients had
TABLE 1 Baseline characteristics of 141 patients undergoing distal
pancreatectomy for pancreatic ductal adenocarcinoma
Male sex 63 (45)
Age [years; mean (SD)] 64 (10)
BMI [kg/m2; mean (SD)] 25 (4)
ASA physical status
1 16 (11)
2 99 (70)
3 23 (16)
4 3 (2)
Previous abdominal surgery 53 (38)
Other organs involved on CT/MRI 29 (21)
Stomach 9 (6)
Spleen 7 (5)
Kidney 4 (3)
Intestine 4 (3)
Two or more adjacent organs 5 (4)
Data are expressed as n (%) unless otherwise specified
SD standard deviation, BMI body mass index, ASA American Society
of Anesthesiologists, CT computed tomography, MRI magnetic res-
onance imaging
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undergone multivisceral resection. The median number of
resected lymph nodes, as shown in Table 2, was not
influenced by hospital volume or the patient’s body mass
index.
Postoperative Outcomes
Details of the postoperative clinical course are shown in
Table 3. Postoperatively, 33 % of patients (n = 46)
developed a major complication. A postoperative pancre-
atic fistula grade B/C occurred in 24 patients (17 %).
Median length of stay was 10 days (IQR 8–15). Postop-
erative 30-day and 90-day mortality were 3 % (n = 4) and
6 % (n = 9), respectively. Three patients (2 %) died within
90 days postoperatively for unknown reasons, which was
not recorded by the hospital where these patients were
operated. In total, 63 patients (45 %) received adjuvant
chemotherapy.
Survival
Median follow-up was 17 months (IQR 8–29), and no
patients were lost to follow-up for survival. In this cohort,
100 patients died and 41 patients were censored for sur-
vival analysis. Postoperative median survival was
17 months (95 % CI 13–21), while 1-, 3-, and 5-year
cumulative survival were 64, 29, and 22 % respectively.
Survival did not differ between patients who did and did
not undergo splenectomy. Survival was worse in patients
who had undergone DP with multivisceral resection
[10 months (95 % CI 6–15) vs. 22 months (95 % CI 17–
27); p\ 0.01]. In the univariable analyses, multivisceral
resection, R1/R2 resection, pT3 stage, a major complica-
tion, and not receiving adjuvant chemotherapy were
associated with worse survival.
In the multivariable analysis, R1/R2 resection, pT3/pT4
stage, a major complication, and not receiving adjuvant
chemotherapy were significant predictors of worse survival
(Table 4). Adding sex and age to the multivariable Cox
regression analysis did not change the statistical signifi-
cance of the included variables.
Subgroup Analyses
Patients who received adjuvant chemotherapy (n = 63)
did not differ from those patients who did not receive
TABLE 2 Operative and pathology outcomes of 141 patients
undergoing distal pancreatectomy for pancreatic ductal
adenocarcinoma
Splenectomy 124 (88)
Multivisceral resection 43 (30)
Stomach 9 (6)
Intestine 5 (4)
Kidney/adrenal gland 5 (4)
Vessel resection 5 (4)
Other 4 (3)
[1 additional resection 15 (11)
Procedure time [min; median (IQR)] 194 (150–270)
Blood loss [min; median (IQR)] 800 (495–1618)
Tumor size [mm; mean (SD)] 44 (23)
Resection margins
R0 70 (50)
R0 in multivisceral resection 17 (40)
R1 64 (45)
R2 7 (5)
Lymph nodes resected [median (IQR)] 8 (4–14)
Positive lymph nodes resected [mean (SD)] 1 (1)
pT stage
1 14 (10)
2 70 (50)
3 52 (37)
4 5 (4)
pN1 stage 74 (53)
pM1 stage 4 (3)
Cancer stage
1A 6 (4)
1B 34 (24)
2A 25 (18)
2B 68 (48)
3 4 (3)
4 4 (3)
Data are expressed as n (%) unless otherwise specified
IQR interquartile range, SD standard deviation
TABLE 3 Postoperative outcomes of 141 patients undergoing distal
pancreatectomy for pancreatic ductal adenocarcinoma
Major complications 46 (33)
Clavien–Dindo 3 35 (25)
Clavien–Dindo 4 5 (4)
Clavien–Dindo 5 6 (4)
Postoperative pancreatic fistula grade B/C 24 (17)
Delayed gastric emptying grade B/C 25 (18)
Postpancreatectomy hemorrhage grade B/C 6 (4)
Surgical site infection 18 (13)
Intensive care unit admission 24 (17)
Length of intensive care unit stay [days; median (IQR)] 2 (2–8)
Length of stay [days; median (IQR)] 10 (8–15)
Readmission within 30 days 25 (18)
Adjuvant chemotherapy 63 (45)
Mortality B30 days postoperatively 4 (3)
Mortality B90 days postoperatively 9 (6)
Data are expressed as n (%) unless otherwise specified
IQR interquartile range
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adjuvant chemotherapy (n = 78) with regard to male sex
[34 (54 %) patients vs. 44 (56 %) patients; p = 0.77],
mean age [63 (SD 11) vs. 65 (SD 9) years; p = 0.43],
ASA physical status 1/2 [51 (81 %) patients vs. 64 (82 %)
patients; p = 0.87], tumor stage [pT1, 9 (14 %) vs. 5 (6 %)
patients; pT2, 33 (52 %) vs. 37 (47 %) patients; pT3, 19
(30 %) vs. 33 (52 %) patients; and pT4, 2 (3 %) vs. 3
(4 %) patients; p = 0.29], the presence of lymph node
metastases [33 (52 %) patients vs. 41 (53 %) patients;
p = 0.98], or tumor size (43 vs. 44 mm; p = 0.68).
Patients with a major complication (n = 46) were less
likely to receive adjuvant chemotherapy compared with
patients without a major complication (n = 95) [14 (30 %)
patients vs. 49 (51 %) patients; p = 0.02]. Furthermore, a
major complication was a predictor of not receiving adju-
vant chemotherapy in a multivariable logistic regression
analysis (odds ratio 2.4, 95 % CI 1.2–1.3; p = 0.02), in
which sex, age, ASA physical status, and a major
complication were included (a laparoscopic approach had a
p value\ 0.2 in a univariable analysis and was therefore
not included in the multivariable analysis). After publica-
tion of the Dutch guideline on pancreatic cancer in 2011,
more patients received adjuvant chemotherapy [30/48
(63 %) vs. 33/93 (35 %); p\ 0.01]. Patients who received
adjuvant chemotherapy had a significantly better median
survival than patients who did not receive adjuvant
chemotherapy [23 months (95 % CI 17–29) vs. 12 months
(95 % CI 6–18); p\ 0.01]. Tumor size and tumor stage
were not associated with the likelihood of undergoing
splenectomy (data not shown). In a sensitivity analysis,
excluding the laparoscopic procedures did not lead to sig-
nificant changes in operative time, blood loss, major
complication rate, radical resection rate, or survival (data
not shown).
DISCUSSION
This multicenter study on DP for PDAC showed a 33 %
major complication rate, a 3 % 30-day mortality, a 6 % 90-
day mortality rate, a 5-year cumulative survival of 22 %,
and a median survival of 17 months. Independent predic-
tors of survival were an R1/R2 resection, a pT3/pT4 stage
tumor, a major complication, and not receiving adjuvant
chemotherapy. These predictors can guide future studies
aimed at improving survival.
Survival in this series was comparable with a recent
multicenter series on DP for PDAC from the US, reporting
a median survival of 16 months in 212 patients from nine
centers (2000–2008).10 Median survival after DP for
PDAC in the recent French series was 35 months among
261 patients from 28 centers (2004–2009), surprisingly
better than reported elsewhere.10,11,23,24 However, time of
death was based on hospital records rather than municipal
records in that study, and information bias may therefore
explain the marked contrast. Although the reported survival
could also be related to a different patient selection process
or strict adherence to the radical antegrade modular pan-
creatosplenectomy (RAMPS) technique, details on both
aspects are lacking in the report.11,25 The radical (R0)
resection rate in our series was low compared with the
literature,10,11 possibly due to the strict definition for R0
resection, including also a C 1 mm circumferential resec-
tion margin. Enhanced adherence to the RAMPS technique
could further improve the rate of R0 resection and hence
increase survival. In our series, the median number of
resected lymph nodes was also comparable with the liter-
ature and was not related to average case-volume or the
patient’s body mass index.10
During the study period, only 45 % of all patients
received adjuvant chemotherapy, compared with 69 % in
TABLE 4 Univariable and multivariable Cox regression analyses for
predictors of survival after distal pancreatectomy for pancreatic ductal
adenocarcinoma
Variable Univariable
analysis
Multivariable
analysis
HR (95 %
CI)
p
value
HR (95 %
CI)
p
value
Female sex 0.88 (0.59–
1.31)
0.52 – –
Age[ 70 years 1.30 (0.85–
1.99)
0.22 – –
ASA physical status 3/4 1.06 (0.64–
1.77)
0.82 – –
Tumor size (cm) 1.03 (0.96–
1.11)
0.39 – –
Laparoscopic approach 1.31 (0.57–
3.00)
0.52 – –
Multivisceral resection 2.04 (1.35–
3.09)
\0.01 –a –a
R1/R2 resection 1.81 (1.22–
2.70)
\0.01 1.61 (1.08–
2.41)
0.02
No. of tumor-positive
lymph nodes
1.06 (0.94–
1.18)
0.35 – –
pN1 stage 1.41 (0.95–
2.10)
0.09 –a –a
pT3/pT4 stage 3.84 (1.71–
8.60)
\0.01 1.92 (1.29–
2.88)
\0.01
Major complication 1.74 (1.16–
2.62)
0.01 1.67 (1.10–
2.51)
0.02
No adjuvant therapy 1.89 (1.23–
2.90)
\0.01 1.51 (1.01–
2.26)
0.045
ASA American Society of Anesthesiologists, HR hazard ratio, CI
confidence interval
a Included in the multivariable analysis but removed during back-
ward selection
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the series from the US and 71 % in the French series.11,23
This might be due to the early years of the study period, as,
in The Netherlands, adjuvant chemotherapy was only
considered standard treatment after August 2011. In 2012
and 2013, the amount of patients receiving adjuvant
chemotherapy increased to 63 %. Despite the overall
higher proportion of patients receiving adjuvant
chemotherapy in the series from the US, similar survival
outcomes were reported.10 As patients who experienced a
major complication after DP were less likely to receive
adjuvant chemotherapy, it is important to focus on pre-
venting surgical complications. Potentially, a laparoscopic
approach could achieve this, although evidence from ran-
domized studies is lacking.20 We could not assess the
influence of neoadjuvant chemotherapy or radiotherapy on
outcomes such as blood loss, resection margins, or mor-
tality, as these treatments were not used within the current
study period. Future studies therefore need to determine its
impact.
In the current series, as well as in previously published
series, incomplete (R1/R2) resection, pT3/T4 stage, and not
receiving adjuvant chemotherapy were significant predic-
tors of worse survival after surgery.10,11,23,24,26 These
results highlight the need for improved surgical technique,
patient selection, and attention for adjuvant chemotherapy.
Because of the influence of receiving chemotherapy on
survival probability, high-quality research on (neo-)adju-
vant treatment for patients undergoing surgery because of
PDAC is warranted. Only one article described multivisceral
resections (21 % of all included DPs) and, in their series,
after univariable analysis, multivisceral resection was asso-
ciated with worse postoperative survival (p\ 0.01);11
however, no quantity of survival worsening, such as median
survival or cumulative survival, was given. Therefore, it is
unknown how much a multivisceral resection contributes to
poor life expectancy (Fig. 1).
In the current series, postoperative morbidity and
hospital stay were comparable with reported outcomes in
the literature.27 This included a 33 % postoperative major
complication rate, a 17 % postoperative pancreatic fistula
rate, and a median hospital stay of approximately 10 days.
The 90-day mortality rate of 6 % is relatively high
compared with the literature, but some previous series
reported mortality up to 6.3 %.27,28 Nonetheless, this
should be considered the upper limit of acceptable mor-
tality after DP. Given the low number of DPs for PDAC
per center in both this and previous series, it could be
questioned whether centralization of DPs could improve
short-term postoperative outcomes, as has been shown for
pancreatoduodenectomy.29 Pancreatic surgery has been
centralized in The Netherlands as of 2007.29 As a con-
sequence, in the first 3 years of this study some patients
may have undergone DP in hospitals other than those of
the DPCG. However, due to low case-volumes during this
period, the total amount of missed patients is expected to
be very low.
A limitation of this study is its retrospective design, with
the risk of information bias, such as underreporting of
study outcomes. Nevertheless, the primary outcome of this
study, i.e. survival, is highly reliable since it was recorded
using the municipal personal records database.
CONCLUSIONS
Survival after DP for PDAC is poor. Independent pre-
dictors of postoperative survival were incomplete tumor
resection, advanced tumor stage, major surgical compli-
cations, and not receiving adjuvant chemotherapy. This
nationwide series on DP for DPAC highlights the impor-
tance of preventing surgical complications, improving
surgical technique, and the use of adjuvant chemotherapy.
Future prospective studies should determine the extent to
which these aforementioned measures can improve
survival.
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